- Renasant Corporation announced that Catherine Mealor would join the company as Executive Vice President in October 2026 and become Chief Financial Officer on January 1, 2027, succeeding long-time CFO Jim Mabry ahead of his early 2027 retirement.
- The appointment brings in a career bank analyst with more than two decades of Southeastern U.S. bank research experience and FASB advisory committee service, potentially influencing how Renasant approaches financial reporting, capital allocation and risk oversight.
- We’ll now examine how bringing in a veteran Southeastern bank analyst as incoming CFO may influence Renasant’s existing investment narrative.
Find 47 companies with promising cash flow potential yet trading below their fair value.
Renasant Investment Narrative Recap
To own Renasant, you need to be comfortable with a regional bank built around the Southeastern U.S., where loan growth, credit quality and merger integration remain the key levers. The appointment of incoming CFO Catherine Mealor looks more continuity than catalyst in the near term, with no clear short term impact on the main driver right now, which is how effectively Renasant converts recent merger scale and improving earnings into sustained profitability while managing regional credit and regulatory risks.
Among recent announcements, the expanded US$250,000,000 share repurchase program stands out alongside the dividend increases, as it directly affects how capital is returned to shareholders. Against that backdrop, bringing in a former bank research analyst as CFO could matter over time for how Renasant balances buybacks, dividends and reinvestment as it pursues merger synergies, digital investments and broader fee income growth.
But even with these positive signals, investors should still be watching the bank’s concentrated exposure to Southeastern credit conditions and regional economic shocks…
Read the full narrative on Renasant (it’s free!)
Renasant’s narrative projects $1.3 billion revenue and $392.7 million earnings by 2029. This requires 6.3% yearly revenue growth and about a $78.6 million earnings increase from $314.1 million today.
Uncover how Renasant’s forecasts yield a $48.00 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Two fair value estimates from the Simply Wall St Community span roughly US$48 to US$54, underlining how differently individual investors can view Renasant’s potential. You will want to weigh those views against the bank’s reliance on high growth Southeastern markets and consider how that exposure could shape future performance over time.
Explore 2 other fair value estimates on Renasant – why the stock might be worth as much as 31% more than the current price!
Decide For Yourself
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
- A great starting point for your Renasant research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Renasant research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Renasant’s overall financial health at a glance.
Seeking Other Investments?
Our daily scans reveal stocks with breakout potential. Don’t miss this chance:
- Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
- Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
Robinhood now earns more from people betting on outcomes than companies. Is that a flaw or a feature?
Q2 had the World cup. Not a signal. Robinhood has hardly moved this year.
Contrarian take: Gambling can only expand as much. If you are keeping a close eye in the image represented here, crypto volumes have shifted to events.
Mitchell Lawler
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picks
Fresh 13F filings are where some investors go to find their next stock pick. The problem is it’s missing some of the most important details for making a good investment.
62
Sep 4, 2026
About NYSE:RNST
Renasant
Operates as a bank holding company for Renasant Bank that provides a range of financial, wealth management, and fiduciary services to retail and commercial customers.
Flawless balance sheet with solid track record and pays a dividend.
Similar Companies
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picksMI
Mitchell Lawler
Great earnings season, but are the earnings real?AN
Andrew Legget
Which payment stocks actually get paid?MI
Mitchell Lawler
Advertisement
Weekly Picks
Lou_Baseneseon Oncolytics Biotech·20 days ago
The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech
Fair Value:US$3.575.9% undervalued
68followersusers have followed this narrative
·1commentusers have commented on this narrative
·18likesusers have liked this narrative
AN
andrei9868on ServiceNow·24 days ago
The Platform Turning Enterprise Chaos into Autonomous Workflows
John_Ericon Vistra·8 days ago
Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here’s the $472 Million Reason They Disagree.
Fair Value:US$291.8748.8% undervalued
52followersusers have followed this narrative
·2commentsusers have commented on this narrative
·20likesusers have liked this narrative
HA
HarishPKon EverQuote·18 days ago
EverQuote and an Asymmetric Investment Opportunity
RecentlyUpdated Narratives
Alhabibon Zevra Therapeutics·about 2 hours ago
revenue is growing while new-patient acquisition has decelerated sharply
John_Ericon IREN·about 8 hours ago
The Bitcoin Miner Who Accidentally Built the Best Real Estate Portfolio in AI
RockeTelleron West Red Lake Gold Mines·about 15 hours ago
This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold
Popular Narratives
AnalystConsensusTargeton NVIDIA·about 1 month ago
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$302.8323.9% undervalued
1384followersusers have followed this narrative
·8commentsusers have commented on this narrative
·35likesusers have liked this narrative
JO
John_Ericon MercadoLibre·3 days ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$3.68k46.2% undervalued
131followersusers have followed this narrative
·3commentsusers have commented on this narrative
·18likesusers have liked this narrative
OSoscargarciaon NVIDIA·3 months ago
